KR20210015883A - 당뇨 제어 및 염증성장질환 치료의 향상을 위한 구조적으로 변형된 지방산 - Google Patents

당뇨 제어 및 염증성장질환 치료의 향상을 위한 구조적으로 변형된 지방산 Download PDF

Info

Publication number
KR20210015883A
KR20210015883A KR1020207037063A KR20207037063A KR20210015883A KR 20210015883 A KR20210015883 A KR 20210015883A KR 1020207037063 A KR1020207037063 A KR 1020207037063A KR 20207037063 A KR20207037063 A KR 20207037063A KR 20210015883 A KR20210015883 A KR 20210015883A
Authority
KR
South Korea
Prior art keywords
compound
group
ibd
formula
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207037063A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 알랜 프레이저
토레 스크재렛
데트레프 스쳐판
Original Assignee
노스씨 테라퓨틱스 비.브이.
바스프 에이에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노스씨 테라퓨틱스 비.브이., 바스프 에이에스 filed Critical 노스씨 테라퓨틱스 비.브이.
Priority to KR1020257032515A priority Critical patent/KR20250150676A/ko
Publication of KR20210015883A publication Critical patent/KR20210015883A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/54—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and unsaturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020207037063A 2018-05-23 2019-05-22 당뇨 제어 및 염증성장질환 치료의 향상을 위한 구조적으로 변형된 지방산 Ceased KR20210015883A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257032515A KR20250150676A (ko) 2018-05-23 2019-05-22 당뇨 제어 및 염증성장질환 치료의 향상을 위한 구조적으로 변형된 지방산

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NO20180714 2018-05-23
NO20180714 2018-05-23
PCT/IB2019/000655 WO2019224602A2 (en) 2018-05-23 2019-05-22 Structurally modified fatty acids for improving glycemic control and treating inflammatory bowel disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257032515A Division KR20250150676A (ko) 2018-05-23 2019-05-22 당뇨 제어 및 염증성장질환 치료의 향상을 위한 구조적으로 변형된 지방산

Publications (1)

Publication Number Publication Date
KR20210015883A true KR20210015883A (ko) 2021-02-10

Family

ID=67688797

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207037063A Ceased KR20210015883A (ko) 2018-05-23 2019-05-22 당뇨 제어 및 염증성장질환 치료의 향상을 위한 구조적으로 변형된 지방산
KR1020257032515A Pending KR20250150676A (ko) 2018-05-23 2019-05-22 당뇨 제어 및 염증성장질환 치료의 향상을 위한 구조적으로 변형된 지방산

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257032515A Pending KR20250150676A (ko) 2018-05-23 2019-05-22 당뇨 제어 및 염증성장질환 치료의 향상을 위한 구조적으로 변형된 지방산

Country Status (8)

Country Link
US (2) US20210290576A1 (https=)
EP (1) EP3796901A2 (https=)
JP (1) JP7508447B2 (https=)
KR (2) KR20210015883A (https=)
CN (1) CN112351775A (https=)
AU (1) AU2019274203B2 (https=)
CA (1) CA3101041A1 (https=)
WO (1) WO2019224602A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230112349A (ko) 2022-01-20 2023-07-27 한국과학기술연구원 삼원계 광활성층 조성물 및 이를 포함하는 유기태양전지

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009061208A1 (en) 2007-11-09 2009-05-14 Pronova Biopharma Norge As Lipid compounds for use in cosmetic products, as food supplement or as a medicament
EP2147910A1 (en) * 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Novel lipid compounds
BRPI1015120B8 (pt) * 2009-05-08 2022-02-15 Basf As Composto lipídico alfa-substituídos, derivados de ácidos graxos beta-oxo poli-insaturados, composição farmacêutica e lipídica e métodos para produzir composto lipídico e ácido 2-((5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaeniloxi)butanóico
EP2526084A1 (en) 2010-01-20 2012-11-28 Pronova BioPharma Norge AS Salicylate fatty acid derivatives
CN102946875A (zh) * 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
PL2961727T3 (pl) 2013-02-28 2017-06-30 Pronova Biopharma Norge As Sposób wytwarzania kwasu 2-((5Z,8Z, 11Z,14Z,17Z)-ejkoza-5,8,11,14,17-pentaenyloksy)butanowego
KR20180010181A (ko) 2015-04-01 2018-01-30 프로노바 바이오파마 너지 에이에스 Apo c3 의 저하를 위한 티아 옥소 화합물의 용도
ES2980790T3 (es) * 2015-04-28 2024-10-03 Basf As Acidos grasos estructuralmente mejorados que contienen azufre para su uso en el tratamiento de la esteatohepatitis no alcohólica

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230112349A (ko) 2022-01-20 2023-07-27 한국과학기술연구원 삼원계 광활성층 조성물 및 이를 포함하는 유기태양전지
US12421250B2 (en) 2022-01-20 2025-09-23 Korea Institute Of Science And Technology Ternary photoactive layer composition and organic solar cell comprising same

Also Published As

Publication number Publication date
JP2021526552A (ja) 2021-10-07
JP7508447B2 (ja) 2024-07-01
US20210290576A1 (en) 2021-09-23
AU2019274203A1 (en) 2021-01-07
EP3796901A2 (en) 2021-03-31
KR20250150676A (ko) 2025-10-20
WO2019224602A3 (en) 2020-03-05
US20260000632A1 (en) 2026-01-01
CA3101041A1 (en) 2019-11-28
CN112351775A (zh) 2021-02-09
AU2019274203B2 (en) 2025-01-02
WO2019224602A2 (en) 2019-11-28

Similar Documents

Publication Publication Date Title
JP6986022B2 (ja) Ｆｘｒアゴニストを使用するための方法
JP6941109B2 (ja) Ｆｘｒアゴニストを使用するための方法
JP7053478B2 (ja) Ｆｘｒアゴニストを使用するための方法
JP2021001173A (ja) リルゾールの舌下製剤
JP2017515854A (ja) カスパーゼ阻害剤による慢性肝疾患の合併症の治療
TW201733582A (zh) Fxr促效劑及arb之組合醫藥
JP2025065389A (ja) 化合物の製剤およびそれらの使用
JP2020536866A (ja) Ａｃｃ阻害剤を含む併用療法
CN115969802A (zh) 含吡非尼酮缓释组合物用于治疗和逆转人脂肪性肝炎的药物用途
JP2022542830A (ja) Ｅｙｐ００１を使用した改善された処置
CA2906196A1 (en) Enantiomerically enriched s-oxprenolol compositions for treating cancer
CN104667283B (zh) 一种治疗血脂异常和动脉粥样硬化的复方药物组合
US20260000632A1 (en) Structurally modified fatty acids for improving glycemic control and treating inflammatory bowel disease
US20140128402A1 (en) Pharmaceutical combination
CN1165314C (zh) 聚乳酸混合物在制备糖尿病治疗剂中的用途
CN120022269A (zh) 鸦胆子苦素d在治疗代谢功能障碍相关脂肪性肝病的应用
JP2007529545A (ja) ダウン症候群の治療法
CN105163732B (zh) 用于治疗眼科疾病和病症的方法
US20100087398A1 (en) Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions
KR20230027388A (ko) 지방간염, 지방증 또는 섬유증의 예방 또는 치료용 복합 제제
EP1305035A1 (en) Naadp analogues for modulating t-cell activity
CN112674028B (zh) 促诱癌剂诱发动物癌症模型建立的方法
CN1115151C (zh) 血管扩张剂和药用稀释剂或载体的混合物在制备用于治疗肝病的药物中用途
KR20230128307A (ko) 비알코올성 지방간염의 치료를 위한 산소-함유 구조적으로개선된 지방산을 포함하는 병용요법
JPWO2008038712A1 (ja) メタボリックシンドロームの治療・予防剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104